Scroll Up
Scroll Down
Play Play Play Play
Murray Waldman
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    TopAbstracts in Depression 07/28/2010 - (DGNews)
    Not All Epilepsy Drugs Linked to Increased Risk of Suicidal Behaviour - (DGNews)
    TopAbstracts in Depression 07/21/2010 - (DGNews)
    Depression Overlooked in Patients With Hepatitis C, May Compromise HCV Therapy - (DGNews)
    TopAbstracts in Depression 07/14/2010 - (DGNews)

    News archive

     Recent webcasts/CME - Depression
    • Practical Strategies to Improve Patient Outcomes: A Case-Based Approach to the Diagnosis and Treatment of Adult Attention Deficit Disorder
    • A 38-Year-Old Mother of Two Who Can Never Find Her Car Keys
    • Case in Point: Treatment-Resistant Depression in Primary Care: New Options for Treatment-Resistant
      Case in Point: Evidence-Based Insights For Epilepsy Management - Comorbid Depressive Disorders in Epilepsy
      Case in Point: Treatment-Resistant Depression in Primary Care: Psychosocial and Nonpharmacologic Interventions in Treatment-Resistant Depression

      Webcasts/CME archive

       Recent cases - Depression
        The Opposite Effects Of Fluvoxamine And Sertraline In The Treatment Of Psychotic Major Depression: A Case Report
        Fluvoxamine Monotherapy For Psychotic Depression: The Potential Role Of Sigma-1 Receptors
        Extrapyramidal Side Effects And Suicidal Ideation Under Fluoxetine Treatment: A Case Report
        Olanzapine And Pulmonary Embolism, A Rare Association: A Case Report
        Anti-Inflammatory Effects Of Antidepressant And Atypical Antipsychotic Medication For The Treatment Of Major Depression And Comorbid Arthritis: A Case Report

        Cases archive
          




        my personal edition > depression > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Citalopram Plus Light Therapy More Effective Than Citalopram Alone For Major Depression

        A DGReview of :"Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial"
        Journal of Clinical Psychiatry

        07/09/2003
        By Mary Beth Nierengarten


        Citalopram (Celexa) combined with light therapy is more effective than citalopram alone as treatment for major depression, say researchers from Italy.

        Because of the delay in onset of efficacy of the selective serotonin reuptake inhibitors (SSRIs), such as citalopram, for the treatment of major depression, there is much interest in finding non-drug, chronobiological interventions, such as light therapy, to supplement and reduce the time it takes for treatment to take effect.

        In a study by Francesco Benedetti, M.D. and colleagues, Università Vita-Salute San Raffaele, Milano, Italy, 21 patients with major depression and 9 patients with bipolar disorder treated with citalopram (10 mg/day on day 1, titrated to 40 mg/day at day 4) were randomised to receive additional 30 minutes of 400 lux green morning light treatment (n=18) or placebo (n=12) during the first 2 weeks of therapy. The Hamilton Rating Scale for Depression (HAM-D), Zung Self-Rating Depression Scale (SDS), and Visual Analogue Scale (VAS) were used to measure outcomes.

        At 4 weeks after initiation of treatment, patients treated with citalopram and additional light therapy showed significant improvement in mood (p<0.05) than patients treated only with citalopram. Improvement was seen during the first days of treatment, and lasted throughout the 4 weeks of the study. Both HAM-D and SDS scores showed significant improvement for the light-therapy: HAM-D and SDS scores showed significant improvement at 1 week (p=0.0084; p=0.0015, respectively), 2 weeks (p=0.0058; p=0.0304, respectively), 3 weeks (p=0.0111; p=0.0155, respectively), and 4 weeks (p=0.0269; p=0.0066, respectively).

        Overall, the patients treated with additional light therapy had a net relative advantage of 26.8% over the placebo group at 4 weeks.

        The authors conclude that adding light therapy to citalopram hastened the effect of citalopram and was more effective than citalopram alone for the treatment of major depression.
        J Clin Psychiatry 2003 Jun;64:6:648-53. "Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send